Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
The analyst downgraded the stock from Buy to Hold, with a price target of $74, down from $83.Truist Securities has downgraded Incyte Corporation (NASDAQ:INCY), noting Jakafi's (ruxolitinib) patent loss approaching in 2028.
賽昂國際證券降低Incyte Corporation (納斯達克:INCY) 的評級，指出Jakafi (ruxolitinib) 的專利將在2028年到期。
Jakafi is Incyte's top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients.
Jakafi 是Incyte的暢銷藥品，適用於成人多紅細胞血癥、成人中度或高風險骨髓纖維化以及成人和兒童激素耐藥性急性移植物抗宿主病。
In second quarter 2024, the drug generated sales of $705.9 million, +3% year-over-year, driven by a 9% increase in paid demand.
在2024年第二季度，該藥物營業收入達到70590萬美元，同比增長3%，受付費需求增長9%的推動。
The analyst downgraded the stock from Buy to Hold, with a price target of $74, down from $83.
分析師將該股票評級由買入調降爲持有，目標價從83美元下調至74美元。
Also Read: Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study.
此外，Incyte發佈了關於淋巴瘤藥物的令人期待的臨床後期研究拓展FDA批准的頂線數據。
With Jakafi's loss of exclusivity approaching, a key concern is whether Incyte's pipeline in immunology, inflammation (I&I), and oncology can compensate for the revenue decline expected from generic competition. While there is long-term growth potential in the company's pipeline—supported by strong Phase 2 data and opportunities for expansion into new indications or combination therapies—the challenge of mitigating the patent cliff remains significant.
隨着Jakafi專利即將失效，一個重要關注點是Incyte在免疫學、炎症和腫瘤學領域的產品線能否彌補由於仿製藥競爭預計造成的營業收入下滑。儘管公司的產品線在長期增長方面有潛力，支持強勁的2期數據以及擴展到新適應症或聯合治療的機會，但應對專利即將失效的挑戰仍然重要。
Additionally, Incyte faces intense competition, particularly in larger markets where it aims to establish a foothold, such as I&I and solid tumors.
此外，Incyte面臨着激烈的競爭，尤其是在試圖在免疫學、炎症和實體腫瘤等較大的市場中建立立足點。
Truist emphasizes the significance of the late-stage results for Povorcitinib in hidradenitis suppurativa (HS), expected in the first half of 2025, as a key factor likely to influence stock performance over the next 12 months.
Truist強調皮膚迸發汗腺炎 (HS)的普伐替尼在2025年上半年有望公佈的後期結果，將成爲影響未來12個月股票表現的關鍵因素。
Additionally, the analyst draws attention to the earlier-stage results expected in the second half of 2024 for Zilurgisertib in myelofibrosis. However, due to Novartis AG's (NYSE:NVS) delays and the challenges, combined with the early development stage of Incyte's programs, Truist is adopting a more cautious stance.
此外，分析師還關注了2024年下半年在真彩金納治重症粘液纖維，Zilurgisertib的早期結果。然而，由於諾華製藥（紐交所：NVS）的延誤和挑戰，以及因塞特項目的早期開發階段，特魯伊斯特採取了一種更爲謹慎的態度。
Price Action: INCY stock is down 0.93% at $65.81 at last check Wednesday.
近期股價行情：INCY股票週三最新報價爲65.81美元，下跌了0.93%。
- General Motors Boosts EV Charging Access: 17,800 Tesla Chargers Now Open For All GM Drivers With New Adapter.
- 通用汽車提升EV充電樁使用權限：現在所有Gm駕駛員都可以使用新適配器開啓17800個特斯拉充電樁。
譯文內容由第三人軟體翻譯。